Management of Atrial Fibrillation Using Immunoglobulin Free Light Chains, Novel Biomarkers of Inflammation

AF is the most common cardiac arrhythmia. There is growing evidence that inflammatory mechanisms play an important role in its pathogenesis; inflammasome activation contributes to the onset and progression of AF. An increase in NOD-like-receptor-pyrin domain-containing-3 (NLRP3) inflammasome activat...

Full description

Saved in:
Bibliographic Details
Main Author: Akira Matsumori
Format: Article
Language:English
Published: Radcliffe Medical Media 2022-11-01
Series:European Cardiology Review
Online Access:https://www.ecrjournal.com/articleindex/ecr.2022.30
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850111126238396416
author Akira Matsumori
author_facet Akira Matsumori
author_sort Akira Matsumori
collection DOAJ
description AF is the most common cardiac arrhythmia. There is growing evidence that inflammatory mechanisms play an important role in its pathogenesis; inflammasome activation contributes to the onset and progression of AF. An increase in NOD-like-receptor-pyrin domain-containing-3 (NLRP3) inflammasome activation releases proinflammatory cytokines that activate nuclear factor (NF)-κB, which regulates the production of immunoglobulin free light chains (FLCs). Serum FLC levels are increased in patients with AF, and FLCs are biomarkers of inflammation. Inflammasomes and NF-κB may be targets for anti-inflammatory strategies to prevent and treat AF when FLC levels are elevated. This review discusses the role of inflammation in the pathogenesis of AF, as well as FLCs as novel inflammatory biomarkers for the management of AF.
format Article
id doaj-art-b70828b375444797a21cccae6396fcaa
institution OA Journals
issn 1758-3756
1758-3764
language English
publishDate 2022-11-01
publisher Radcliffe Medical Media
record_format Article
series European Cardiology Review
spelling doaj-art-b70828b375444797a21cccae6396fcaa2025-08-20T02:37:41ZengRadcliffe Medical MediaEuropean Cardiology Review1758-37561758-37642022-11-011710.15420/ecr.2022.30Management of Atrial Fibrillation Using Immunoglobulin Free Light Chains, Novel Biomarkers of InflammationAkira Matsumori0Clinical Research Institute, National Hospital Organization, Kyoto Medical Center, Kyoto, JapanAF is the most common cardiac arrhythmia. There is growing evidence that inflammatory mechanisms play an important role in its pathogenesis; inflammasome activation contributes to the onset and progression of AF. An increase in NOD-like-receptor-pyrin domain-containing-3 (NLRP3) inflammasome activation releases proinflammatory cytokines that activate nuclear factor (NF)-κB, which regulates the production of immunoglobulin free light chains (FLCs). Serum FLC levels are increased in patients with AF, and FLCs are biomarkers of inflammation. Inflammasomes and NF-κB may be targets for anti-inflammatory strategies to prevent and treat AF when FLC levels are elevated. This review discusses the role of inflammation in the pathogenesis of AF, as well as FLCs as novel inflammatory biomarkers for the management of AF.https://www.ecrjournal.com/articleindex/ecr.2022.30
spellingShingle Akira Matsumori
Management of Atrial Fibrillation Using Immunoglobulin Free Light Chains, Novel Biomarkers of Inflammation
European Cardiology Review
title Management of Atrial Fibrillation Using Immunoglobulin Free Light Chains, Novel Biomarkers of Inflammation
title_full Management of Atrial Fibrillation Using Immunoglobulin Free Light Chains, Novel Biomarkers of Inflammation
title_fullStr Management of Atrial Fibrillation Using Immunoglobulin Free Light Chains, Novel Biomarkers of Inflammation
title_full_unstemmed Management of Atrial Fibrillation Using Immunoglobulin Free Light Chains, Novel Biomarkers of Inflammation
title_short Management of Atrial Fibrillation Using Immunoglobulin Free Light Chains, Novel Biomarkers of Inflammation
title_sort management of atrial fibrillation using immunoglobulin free light chains novel biomarkers of inflammation
url https://www.ecrjournal.com/articleindex/ecr.2022.30
work_keys_str_mv AT akiramatsumori managementofatrialfibrillationusingimmunoglobulinfreelightchainsnovelbiomarkersofinflammation